---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-302045"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-07-13T20:19:36+00:00"
generated_at: "2026-07-13T20:20:09.099574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Erasca reports 57% uORR at 8 weeks for ERAS-0015 in KRAS G12X PDAC; plans pivotal trials in 2027

## Summary
- 57% uORR at 8 weeks in 2L+ KRAS G12X PDAC at 32 mg QD RDE (N=7).
- Safety: mostly low-grade TRAEs, no DLTs, no discontinuations due to TRAEs; median relative dose intensity 100%.
- Combination with panitumumab in mCRC: no DLTs in 16 mg cohort; dose escalation ongoing.
- Plans: registration-enabling trial in NSCLC 2L+ in H1 2027; Phase 3 pivotal in PDAC 1L in 2027; Phase 3 pivotal in RAS-mutant NSCLC in H2 2027/H1 2028.
- One Grade 3 pneumonitis event progressed to Grade 5 after withdrawal of supportive care.

## SEC filing metadata
- accession: 0001193125-26-302045
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-07-13T20:19:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/0001193125-26-302045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/d54726d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-302045
- JSON: https://secwatch.observer/filing/0001193125-26-302045.json
- Plain text: https://secwatch.observer/filing/0001193125-26-302045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.